One Day Advisor

Key Takeaways: Merck & Co. led global pharma R&D spending with $15.8 billion , focusing heavily on post-Keytruda pipeline strategy. Average major pharma drug development costs reached $2.23 billion per asset , driving higher R&D intensity across the sector. Key sector priorities include immuno-oncology, ADCs (antibody-drug conjugates), GLP-1 obesity therapies , and strategic bolt-on acquisitions. The global pharmaceutical industry experienced major strategic realignments in research and development (R&D) investments. As blockbuster patents approach expiration and trial costs rise, top pharmaceutical companies are shifting from massive mega-mergers toward targeted pipeline deals, clinical acceleration, and novel therapeutic modalities. Bristol Myers Squibb, Johnson & Johnson, Pfizer, Merck, AbbVie and Roche all cut their R&D spending last year compared to 2024, some by as much as 29%. Others did boost spending, but by marginal amounts...

Posted by Editorial Team  |  Originally published January 2025  |  Updated July 23, 2026 The relationship between Bitcoin and the Nasdaq has moved from theory to daily market reality. As institutional capital, exchange-traded funds, and Nasdaq-listed crypto proxies have deepened the plumbing between digital assets and traditional equities, Bitcoin now trades less like an independent asset class and more like a leveraged extension of the tech sector. This update walks through where the correlation stands as of July 2026, how it got here, and what it means for anyone using Bitcoin as a portfolio diversifier. Quick Answer: As of July 2026, Bitcoin's 30-day correlation with the Nasdaq and S&P 500 is running near 0.85–0.88 — one of the highest readings on record and well above its roughly 0.54 five-year average . Bitcoin is trading in the mid-$60,000s while the Nasdaq Composite holds near record territory above 26,000. For investors, this means Bitcoin is ...

Update note (July 21, 2026): This article, first published November 23, 2025, has been fully revised with second-quarter 2026 earnings, current market capitalizations, and refreshed ETF performance data. The biggest changes: Eli Lilly's market cap climbed past $1 trillion, CVS Health's stock staged a dramatic recovery, and healthcare-sector ETF returns cooled sharply from their 2025 pace while consumer-staples ETFs swung back into positive territory. Details below. Quick Answer As of July 2026, UnitedHealth Group leads healthcare by revenue (~$450B TTM) while Eli Lilly leads by market cap (~$1.05–1.10 trillion). In food, Nestlé remains the revenue leader (~$113–115B), with JBS newly cracking the top 10 in place of Bunge. Combined healthcare market cap (~$2.9T) now outweighs food (~$948B) by roughly 3-to-1 — an even wider gap than in late 2025 — even though healthcare-sector ETF returns have cooled in 2026 while consumer-staples ETFs have rebounded into double-dig...